Last quarter (Q3 2024), Quest Pharmatech's total revenue was C$―, a decrease of ― from the same quarter last year. In Q3, Quest Pharmatech's net income was C$-2.51M. See Quest Pharmatech’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jan 23	Jan 22	Jan 21	Jan 20	Jan 19
Total Revenue	C$ 15.72K	-	-	-	C$ 0.00	C$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	C$ 15.72K	-	-	-	-	-
Operating Expense	C$ 188.74K	C$ 834.22K	-	C$ 1.07M	C$ 13.63M	C$ 9.04M
Operating Income	C$ -173.02K	C$ -834.22K	-	C$ -1.07M	C$ -13.63M	C$ -9.04M
Net Non Operating Interest Income Expense	C$ -20.56K	C$ -21.00K	-	C$ 5.94K	C$ 33.19K	C$ 152.95K
Other Income Expense	C$ 22.06M	C$ 6.48M	-	C$ 191.14M	C$ 346.95K	C$ 247.63K
Pretax Income	C$ -22.26M	C$ -7.33M	-	C$ 190.06M	C$ -13.25M	C$ -8.64M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	C$ -1.94M	C$ -3.10M	-	C$ 164.17M	-	-
Net Income Common Stockholders	C$ -22.26M	C$ -7.33M	-	C$ 190.06M	C$ -6.18M	C$ -4.39M
Basic EPS	C$ -0.13	C$ -0.04	-	C$ 1.13	C$ -0.04	C$ -0.03
Diluted EPS	C$ -0.13	C$ -0.04	-	C$ 1.11	C$ -0.04	C$ -0.03
Basic Average Shares	C$ 675.17M	C$ 168.40M	-	C$ 167.79M	C$ 167.40M	C$ 167.18M
Diluted Average Shares	C$ 675.17M	C$ 168.40M	-	C$ 167.79M	C$ 167.40M	C$ 167.18M
Dividend Per Share	-	-	-	-	C$ 0.00	C$ 0.00
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	C$ 188.74K	C$ 834.22K	-	C$ -1.07M	C$ 13.63M	C$ 9.04M
Net Income From Continuing And Discontinued Operation	C$ -22.26M	C$ -7.33M	-	C$ 190.06M	C$ -6.18M	C$ -4.39M
Normalized Income	C$ -16.36M	C$ -5.39M	C$ -85.04M	C$ 11.38M	C$ -6.54M	C$ -4.93M
Interest Expense	-	-	-	-	C$ 13.74K	C$ 4.42K
EBIT	C$ -22.24M	C$ -7.31M	C$ -85.03M	C$ 190.07M	C$ -13.24M	C$ -8.64M
EBITDA	C$ -22.23M	C$ -7.30M	C$ -84.99M	C$ 190.11M	C$ -13.20M	C$ -8.63M

Currency in CAD

Quest Pharmatech Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing